|
Name |
1-Acetyl-2-[(acetyloxy)methyl]-5-(6-amino-9h-purin-9-yl)pyrrolidine-3,4-diyl diacetate
|
| Molecular Formula | C18H22N6O7 | |
| IUPAC Name* |
[1-acetyl-3,4-diacetyloxy-5-(6-aminopurin-9-yl)pyrrolidin-2-yl]methyl acetate
|
|
| SMILES |
CC(=O)N1C(C(C(C1N2C=NC3=C(N=CN=C32)N)OC(=O)C)OC(=O)C)COC(=O)C
|
|
| InChI |
InChI=1S/C18H22N6O7/c1-8(25)24-12(5-29-9(2)26)14(30-10(3)27)15(31-11(4)28)18(24)23-7-22-13-16(19)20-6-21-17(13)23/h6-7,12,14-15,18H,5H2,1-4H3,(H2,19,20,21)
|
|
| InChIKey |
BFPSTZZUEPACCS-UHFFFAOYSA-N
|
|
| Synonyms |
13144-03-1; 1-acetyl-2-[(acetyloxy)methyl]-5-(6-amino-9h-purin-9-yl)pyrrolidine-3,4-diyl diacetate; NSC107178; DTXSID30296030; NSC-107178
|
|
| CAS | 13144-03-1 | |
| PubChem CID | 267644 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 434.4 | ALogp: | -1.1 |
| HBD: | 1 | HBA: | 11 |
| Rotatable Bonds: | 8 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 169.0 | Aromatic Rings: | 3 |
| Heavy Atoms: | 31 | QED Weighted: | 0.496 |
| Caco-2 Permeability: | -5.979 | MDCK Permeability: | 0.00005030 |
| Pgp-inhibitor: | 0.019 | Pgp-substrate: | 0.995 |
| Human Intestinal Absorption (HIA): | 0.995 | 20% Bioavailability (F20%): | 0.987 |
| 30% Bioavailability (F30%): | 0.99 |
| Blood-Brain-Barrier Penetration (BBB): | 0.56 | Plasma Protein Binding (PPB): | 15.13% |
| Volume Distribution (VD): | 0.642 | Fu: | 73.70% |
| CYP1A2-inhibitor: | 0.01 | CYP1A2-substrate: | 0.034 |
| CYP2C19-inhibitor: | 0.072 | CYP2C19-substrate: | 0.052 |
| CYP2C9-inhibitor: | 0.008 | CYP2C9-substrate: | 0.06 |
| CYP2D6-inhibitor: | 0.374 | CYP2D6-substrate: | 0.026 |
| CYP3A4-inhibitor: | 0.049 | CYP3A4-substrate: | 0.152 |
| Clearance (CL): | 1.948 | Half-life (T1/2): | 0.878 |
| hERG Blockers: | 0.009 | Human Hepatotoxicity (H-HT): | 0.963 |
| Drug-inuced Liver Injury (DILI): | 0.991 | AMES Toxicity: | 0.02 |
| Rat Oral Acute Toxicity: | 0.832 | Maximum Recommended Daily Dose: | 0.028 |
| Skin Sensitization: | 0.464 | Carcinogencity: | 0.052 |
| Eye Corrosion: | 0.004 | Eye Irritation: | 0.023 |
| Respiratory Toxicity: | 0.901 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002667 | ![]() |
0.321 | D0OL7F | ![]() |
0.413 | ||
| ENC000635 | ![]() |
0.317 | D09SIK | ![]() |
0.400 | ||
| ENC001014 | ![]() |
0.306 | D0L2UN | ![]() |
0.350 | ||
| ENC002259 | ![]() |
0.271 | D06ACW | ![]() |
0.324 | ||
| ENC002198 | ![]() |
0.252 | D06IAR | ![]() |
0.317 | ||
| ENC003484 | ![]() |
0.241 | D0NI0C | ![]() |
0.317 | ||
| ENC005790 | ![]() |
0.239 | D01BYB | ![]() |
0.315 | ||
| ENC001480 | ![]() |
0.237 | D0U3YU | ![]() |
0.306 | ||
| ENC003278 | ![]() |
0.237 | D0ML1F | ![]() |
0.304 | ||
| ENC002632 | ![]() |
0.234 | D0R3FP | ![]() |
0.299 | ||